Not Yet RecruitingPhase 4

The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLD

80 participantsStarted 2026-05-01

Plain-language summary

To compare the efficacy and safety of the combination of alogliptin and actoplus met with that of actoplus met alone in improving the glucose and lipid metabolism and pancreatic function in T2DM patients complicated with MAFLD.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Clinical diagnosis of T2DM * Clinical diagnosis of MAFLD * HbA1c: 6.5-9.5% * BMI: 19-35 kg/m2 * No hypoglycemic drugs or insulin have been used within half a year Exclusion Criteria: * Severe infections, surgeries and other emergency * Other types of diabetes * Severe cardiovascular, brain, liver and kidney disorders * Malignant tumor

What they're measuring

hemoglobin A1c

Timeframe: 6 months of treatment

Trial details

NCT IDNCT07289750

SponsorThe Fourth Affiliated Hospital of Zhejiang University School of Medicine

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-08-31

View on ClinicalTrials.gov More T2DM trials